UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 125

Sortiert nach

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody

Journal of clinical oncology, 2019-10, Vol.37 (30), p.JCO1900318-2737

2019

Volltextzugriff (PDF)

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy

The oncologist (Dayton, Ohio), 2019-04, Vol.24 (4), p.563-569

2019

Volltextzugriff (PDF)

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy

The oncologist (Dayton, Ohio), 2017-06, Vol.22 (6), p.743-749

2017

Volltextzugriff (PDF)

The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention

The New England journal of medicine, 2011-07, Vol.365 (2), p.97-99

2011

Volltextzugriff (PDF)

Accelerated Approval of Oncology Products: The Food and Drug Administration Experience

JNCI : Journal of the National Cancer Institute, 2011-04, Vol.103 (8), p.636-644

2011

Volltextzugriff (PDF)

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

Clinical cancer research, 2011-02, Vol.17 (4), p.907-917

2011

Volltextzugriff (PDF)

U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer

The oncologist (Dayton, Ohio), 2015-08, Vol.20 (8), p.960-966

2015

Volltextzugriff (PDF)

Under‐representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993‐2013

Cancer, 2014-10, Vol.120 (19), p.3025-3032

2014

Volltextzugriff (PDF)

Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells

Proceedings of the National Academy of Sciences - PNAS, 2011-07, Vol.108 (29), p.11878-11883

2011

Volltextzugriff (PDF)

Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2010-04, Vol.28 (12), p.2070-2076

2010

Volltextzugriff (PDF)

Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma

The oncologist (Dayton, Ohio), 2018-02, Vol.23 (2), p.139-142

2018

Volltextzugriff (PDF)

Detection of let-7a microRNA by real-time PCR in gastric carcinoma

World journal of gastroenterology : WJG, 2007-05, Vol.13 (20), p.2883

2007

Volltextzugriff (PDF)

Differential Control of Glucocorticoid Receptor Hormone-Binding Function by Tetratricopeptide Repeat (TPR) Proteins and the Immunosuppressive Ligand FK506

Biochemistry (Easton), 2005-02, Vol.44 (6), p.2030-2038

2005

Volltextzugriff (PDF)

Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer

BJU international, 2016-10, Vol.118 (4), p.590-597

2016

Volltextzugriff (PDF)

Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency

Therapeutic innovation & regulatory science, 2022-09, Vol.56 (5), p.753-764

2022

Volltextzugriff (PDF)

Seven-day triple therapy is a better choice for Helicobacter pylori eradication in regions with low antibiotic resistance

World journal of gastroenterology : WJG, 2015-12, Vol.21 (46), p.13073-13079

2015

Volltextzugriff (PDF)

Comparison of Good Clinical Practice Inspection Processes for Marketing Applications Between the United States Food and Drug Administration and the European Medicines Agency

Therapeutic innovation & regulatory science, 2023-01, Vol.57 (1), p.79-85

2023

Volltextzugriff (PDF)

Food and Drug Administration process for development and approval of drugs and radiopharmaceuticals: Treatments in urologic oncology

Urologic oncology, 2015-03, Vol.33 (3), p.137-142

2015

Volltextzugriff (PDF)

Centralized isolation of Helicobacter pylori from multiple centers and transport condition influences

World journal of gastroenterology : WJG, 2015-01, Vol.21 (3), p.944-952

2015

Volltextzugriff (PDF)

Partners of patients with ulcerative colitis exhibit a biologically relevant dysbiosis in fecal microbial metacommunities

World journal of gastroenterology : WJG, 2017-07, Vol.23 (25), p.4624-4631

2017

Volltextzugriff (PDF)

Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary

Clinical cancer research, 2013-12, Vol.19 (24), p.6650-6656

2013

Volltextzugriff (PDF)

Correction to: Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency

Therapeutic innovation & regulatory science, 2022-09, Vol.56 (5), p.767-767

2022

Volltextzugriff (PDF)

Publisher Correction: Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency

Therapeutic innovation & regulatory science, 2022-09, Vol.56 (5), p.765-766

2022

Volltextzugriff (PDF)

A new first step in activation of steroid receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins

The Journal of biological chemistry, 2002-02, Vol.277 (7), p.4597-4600

2002

Volltextzugriff (PDF)

1 – 25 von 125

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(103)
Mit Volltextzugriff
(116)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(80)
Life Sciences & Biomedicine
(62)
Humans
(51)
Male
(37)
Adult
(23)
Female
(23)
Middle Aged
(23)
Aged
(22)
Oncology
(18)
Animals
(16)
United States
(13)
Technology
(12)
Aged, 80 And Over
(11)
General & Internal Medicine
(11)
Medicine, General & Internal
(11)
United States Food And Drug Administration
(11)
China
(10)
Mice
(10)
Physical Sciences
(10)
Treatment Outcome
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy

The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention

Accelerated Approval of Oncology Products: The Food and Drug Administration Experience

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer

Under‐representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993‐2013

Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells

Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma

Detection of let-7a microRNA by real-time PCR in gastric carcinoma

Differential Control of Glucocorticoid Receptor Hormone-Binding Function by Tetratricopeptide Repeat (TPR) Proteins and the Immunosuppressive Ligand FK506

Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer

Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency

Seven-day triple therapy is a better choice for Helicobacter pylori eradication in regions with low antibiotic resistance

Comparison of Good Clinical Practice Inspection Processes for Marketing Applications Between the United States Food and Drug Administration and the European Medicines Agency

Food and Drug Administration process for development and approval of drugs and radiopharmaceuticals: Treatments in urologic oncology

Centralized isolation of Helicobacter pylori from multiple centers and transport condition influences

Partners of patients with ulcerative colitis exhibit a biologically relevant dysbiosis in fecal microbial metacommunities

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary

Correction to: Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency

Publisher Correction: Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency

A new first step in activation of steroid receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins

Suchergebnisse filtern